Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study

<div>Drug retention rate on adalimumab treatment, overall (upper box) and stratified according to concomitant use of DMARDs vs. adalimumab in monotherapy (lower box). ADA: adalimumab; DMARDs: disease-modifying antirheumatic drugs.</div>

Mediators of Inflammation

fig3

Figure 3

Figure 3: Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 

Figure 3 | Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 